Organization · Venture Capital
Claris Ventures
Claris Ventures is a venture capital firm based in Torino, Italy, focusing on early-stage investments in biopharma companies addressing unmet clinical needs. The firm specializes in therapeutic areas such as oncology, immunology, and rare diseases.
Overview
What Claris Ventures does
What Claris Ventures is
Claris Ventures is a venture capital firm based in Torino, Italy, focusing on early-stage investments in biopharma companies addressing unmet clinical needs. The firm specializes in therapeutic areas such as oncology, immunology, and rare diseases.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- May 3, 2026
Official channels
Find Claris Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Claris Ventures as a funder
Investment thesis
Claris Ventures invests in innovative therapeutic programs with strong science and the potential to address highly unmet patient needs, focusing on early-stage biopharma companies.
Focus narrative
Claris Ventures focuses on equity investments in early-stage biopharma companies, particularly in therapeutic areas such as oncology, immunology, and rare diseases. The firm provides capital, expertise, and hands-on support to facilitate clinical development programs and value creation based on clinical evidence, managing specialized venture capital funds like Claris Biotech I and Claris Biotech II.
Value beyond capital
Claris Ventures provides not only capital but also hands-on support in project management, finance, strategic development, and clinical-development planning, facilitating the growth and success of its portfolio companies.
Focus and fit
- Stages
- Seed · Series A
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 10
Portfolio context
Notable portfolio companies include: Kither Biotech: Develops new drugs for incurable respiratory diseases. NeoPhore: Focuses on next-generation cancer immunotherapies. Resalis Therapeutics: Works on first-in-class non-coding RNA targeting compounds for obesity. Heqet Therapeutics: Develops RNA-based therapies to induce cardiac regeneration. Iama Therapeutics: Innovates medicines for central nervous system disorders. Sibylla Biotech: Operates a drug discovery platform to unveil a new class of small-molecule degraders. Page Therapeutics: Develops innovative compounds that prevent metastasis. Repron Therapeutics: Focuses on developing first-in-class therapeutics to silence transcriptional factors of oncogenes. ALKemist Bio: Works on TCR-based therapies to treat ALK positive tumors. Lever Bio: Reprograms the tumor microenvironment to enhance cancer immunotherapy potential. Haptena Therapeutics: Develops next-generation immunotherapies for genetically defined cancers.
Common questions
What to know about Claris Ventures
Upseed classifies Claris Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 3, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.